Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Porta

Showing results (171-180 of 229) with videos related to

Pageof 23
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancerM Aapro, F Andre, K Blackwell, et al.
Bone Marrow Transplantation|January 27, 2004
Impaired bone marrow hematopoietic progenitor cell function in rheumatoid arthritis patients candidated to autologous hematopoietic stem cell transplantationC Porta, R Caporali, O Epis, et al.
Minerva Chirurgica|October 31, 1992
[Hemodynamic reserve in carotid surgery and the use of "superselective" shunt]D Palombo, C Porta, F Peinetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2019
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†B Escudier, C Porta, M Schmidinger, et al.
Journal of Molecular Recognition : JMR|May 24, 2000
Influence of three-dimensional structure on the immunogenicity of a peptide expressed on the surface of a plant virusK M Taylor, T Lin, C Porta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2021
ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinomaT Powles, L Albiges, A Bex, et al.
British Journal of Cancer|March 31, 2011
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trialG Procopio, E Verzoni, S Bracarda, et al.
Minerva Medica|March 17, 1985
[Our experience with embolism and acute arterial thrombosis of the extremities]G Emanuelli, G Real, F Scotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2013
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trialG Procopio, E Verzoni, S Bracarda, et al.
Nature Structural & Molecular Biology|June 1, 2023
Structural basis for control of bacterial RNA polymerase pausing by a riboswitch and its ligandAdrien Chauvier, Jason C Porta, Indrajit Deb, et al.
Pageof 23

Showing results (171-180 of 229) with videos related to

Sort By:
Pageof 23
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancerM Aapro, F Andre, K Blackwell, et al.
Bone Marrow Transplantation|January 27, 2004
Impaired bone marrow hematopoietic progenitor cell function in rheumatoid arthritis patients candidated to autologous hematopoietic stem cell transplantationC Porta, R Caporali, O Epis, et al.
Minerva Chirurgica|October 31, 1992
[Hemodynamic reserve in carotid surgery and the use of "superselective" shunt]D Palombo, C Porta, F Peinetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2019
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†B Escudier, C Porta, M Schmidinger, et al.
Journal of Molecular Recognition : JMR|May 24, 2000
Influence of three-dimensional structure on the immunogenicity of a peptide expressed on the surface of a plant virusK M Taylor, T Lin, C Porta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2021
ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinomaT Powles, L Albiges, A Bex, et al.
British Journal of Cancer|March 31, 2011
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trialG Procopio, E Verzoni, S Bracarda, et al.
Minerva Medica|March 17, 1985
[Our experience with embolism and acute arterial thrombosis of the extremities]G Emanuelli, G Real, F Scotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2013
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trialG Procopio, E Verzoni, S Bracarda, et al.
Nature Structural & Molecular Biology|June 1, 2023
Structural basis for control of bacterial RNA polymerase pausing by a riboswitch and its ligandAdrien Chauvier, Jason C Porta, Indrajit Deb, et al.
Pageof 23